TNGX

NEUTRALProduct

Tango Therapeutics, Inc.

2026-04-16

Price

$25.04

-1.14%

This is the 2026-04-16 snapshot — the signals and analysis for TNGX as of this single trading day.

View full TNGX research hub →

Score1.5Noise

Signals2/8 DNA0/13 Act · 2/4 Risk

SentimentNEUTRALScore: 8

Volume0.8xvs 20d avg

Analysis

TNGX is experiencing High-Conviction Price Discovery driven by stellar Phase 3 trial results for its lead PRMT5 inhibitor, vopimetostat, and the strategic appointment of a new CFO to accelerate commercialization. This fundamental strength is perfectly captured by the PERFECT_STACK and GOLDEN_CROSS technical signals, illustrating sustained institutional buying that is easily absorbing recent insider profit-taking. Furthermore, the current RISK_ON (EARNINGS) regime and exceptionally calm credit markets provide an ideal macroeconomic tailwind for high-beta, clinical-stage biotech stocks to break out. Ultimately, buyers are confidently ignoring broader geopolitical noise to aggressively price in this structural product catalyst.

Fired Signals

GOLDEN CROSSPERFECT STACKWEAK FINISHEXTENSION

Key Takeaways

Actionable Thesis: Capitalize on High-Conviction Price Discovery fueled by vopimetostat's Phase 3 success and a wave of aggressive analyst price target upgrades (up to $28).
Key Risk: Substantial insider selling by executives following the stock's massive +1,600% 1-year run could introduce sudden overhead supply.
What to Watch: Maintain strict risk management around the $18.96 support level while tracking the upcoming May 11 earnings call for RAS(ON) combination trial updates.

← Back to 2026-04-16 View Full TNGX History →Yahoo Finance &nearr;